Pharsight

Noven Pharms Inc patents expiration

1. Daytrana patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9034370 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic polymers
Oct, 2025

(2 years from now)

US9668981 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic based polymers
Oct, 2025

(2 years from now)

US8632802 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic polymers
Oct, 2025

(2 years from now)

Drugs and Companies using METHYLPHENIDATE ingredient

Market Authorisation Date: 06 April, 2006

Treatment: Method for transdermally delivering a drug to a user in need thereof

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

How can I launch a generic of DAYTRANA before it's drug patent expiration?
More Information on Dosage

DAYTRANA family patents

Family Patents

2. Xelstrym patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8632802 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic polymers
Oct, 2025

(2 years from now)

US9034370 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic polymers
Oct, 2025

(2 years from now)

US8591941 NOVEN PHARMS INC Transdermal drug delivery device including an occlusive backing
Oct, 2025

(2 years from now)

US9456993 NOVEN PHARMS INC Compositions and methods for transdermal delivery of amphetamine
Oct, 2033

(10 years from now)

US9474722 NOVEN PHARMS INC Compositions and methods for transdermal delivery of amphetamine
Oct, 2033

(10 years from now)

US11559501 NOVEN PHARMS INC Transdermal amphetamine compositions with low levels of carbamate
Jan, 2042

(18 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Mar 22, 2025

Drugs and Companies using DEXTROAMPHETAMINE ingredient

Market Authorisation Date: 22 March, 2022

Treatment: A method of treating attention deficit hyperactivity disorder by administering a transdermal composition containing amphetamine

Dosage: SYSTEM;TRANSDERMAL

More Information on Dosage

XELSTRYM family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic